The New York Times' Nicholas Wade likens NIH's funding of basic research to the management of a stock index fund — "they buy everything in the market, and the few spectacular winners make up for all the disasters." In fact, basic research is so risky, he adds, that only the government is interested in paying for it. "It is a venture that produces far fewer hits than misses," Wade says.